Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994069 · ClinicalTrials.gov registry record · Phase 2
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
A Phase 2 study of Head and Neck Cancer and Carcinoma, Squamous Cell, sponsored by Susanne Arnold.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02994069 is a Phase 2 study of Head and Neck Cancer and Carcinoma, Squamous Cell that is active but no longer recruiting, run by Susanne Arnold. The registered enrollment target is 80 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02994069, a Phase 2 study of Head and Neck Cancer and Carcinoma, Squamous Cell, is active but no longer recruiting, sponsored by Susanne Arnold.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced SCCHN. The relationship between cisplatin toxicity and the level of reactive oxygen species generated by the drug in subjects with squamous cell carcinoma of the head and neck treated on this trial.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION XRT
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02994069
The ClinicalTrials.gov registry entry for NCT02994069 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Susanne Arnold, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT02994069 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT02994069 about?
NCT02994069 is a clinical study titled "Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers". Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced SCCHN. The relationship between cisplatin toxicity and the level of reac...
What is the current status of trial NCT02994069?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-04-11. Estimated completion is 2029-10-31.
What conditions does trial NCT02994069 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Carcinoma, Squamous Cell.
What interventions are being tested in trial NCT02994069?
The interventions under investigation include: Cisplatin (DRUG), XRT (RADIATION).
Who is sponsoring clinical trial NCT02994069?
This trial is sponsored by Susanne Arnold, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02994069 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.